Moderna, Inc. vs SailPoint Inc. Common Stock — how do they compare? Moderna, Inc. trades at $223.17 (market cap $86.33B), while SailPoint Inc. Common Stock trades at $19 (market cap $11.06B). The key difference: Moderna, Inc. is far larger — about 7.8× SailPoint Inc. Common Stock's market cap, and Moderna, Inc. is trading nearer its 52-week high, SailPoint Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and SailPoint Inc. Common Stock for 0 Days on average.
| MRNA | SAIL | |
|---|---|---|
Market Cap | $86.33B | $11.06B |
Volume | 13,361,426 | 3,269,663 |
Sector | Health | Technology |
52-Week High | $226.30 | $22.85 |
52-Week Low | $22.36 | $10.49 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $82.48B | $10.76B |
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $216.25, up 1.17% with a bullish technical signal and recent Nasdaq-100 inclusion driving momentum. Despite beating Q2 2026 EPS estimates, the company faces fundamental challenges with a net income margin of -142.58% and declining revenue from $18.9B in 2022 to $1.92B in 2025. The stock's 500% rally in 2026 has pushed valuations to elevated levels with a P/S of 38.5, creating divergence between technical strength and financial performance.
The outlook remains polarized with Nasdaq inclusion providing institutional support but valuation concerns capping upside. Investment opportunity lies in the cancer vaccine pipeline, while risks include sustained profitability challenges and competitive pressures. Analyst consensus at $115.70 suggests significant downside from current levels, with only 28% recommending buy ratings amid ongoing operational cash flow deficits.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →SailPoint, Inc. develops identity security software that helps enterprises manage and govern access to applications and data across users, machines, and AI agents. Its unified identity security platform combines automation and intelligence to control identity-related risk at scale for large organizations.
Read more on SAIL →